Summary of Purpose
When to start anticoagulation in patients with an acute ischaemic stroke and atrial fibrillation (AF) is a relevant unanswered question in clinical practice. Direct oral anticoagulants (DOACs) are highly effective for secondary stroke prevention in these patients, but DOACs were never initiated <7 days after stroke onset in recent trials. The ELAN trial will determine the net benefit of early versus late...Read More →
The following dates are available for this trial. Trial information last updated on 23 April 2018.
|6 Nov 2017||7 Apr 2017||30 Aug 2021||31 Oct 2021||1 Apr 2018||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)
- Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)